RHEUMATOLOGY DEPARTMENT – CLINICAL TRIALS AND RESEARCH
Double blind randomized controlled trial of effectiveness and safety of nintedanib versus placebo for at least 52 weeks in patients with Interstitial Lung Disease and Systemic Sclerosis (199.214)
Support: Boehringer Ingelheim Ellas
PI: Professor Petros Sfikakis
Open label evaluation study of long term safety of nintedanib in patients with Interstitial Lung Disease and Systemic Sclerosis (199.225)
Support: Boehringer Ingelheim Ellas
PI: Professor Petros Sfikakis
Double blind randomized controlled trial comparing sc administered drug BI 655064 versus placebo on patients with Systemic Lupus Erythematosus related nephritis
PI: Professor Petros Sfikakis
Phase 3 Randomised double blind controlled trial comparing ABT-494 to placebo for patients with moderate to severe Rheumatoid Arthritis under standard dose csDMARD who have failed or developed side effects while on bDMARD
PI: Professor Petros Sfikakis
Phase 3 Randomised double blind controlled trial comparing ΑΒΤ-494 once daily monotherapy to methotrexate monotherapy in patients with moderate to severe Rheumatoid Arthritis who had in the past received methotrexate
PI: Professor Petros Sfikakis
Phase 3 Randomised double blind controlled trial comparing ΑΒΤ-494 once daily monotherapy to placebo and to adalimumab in patients with Psoriasic Arthritis who had in the past failed treatment with at least one DMARD – SELECT – PsA 1
PI: Professor Petros Sfikakis
Multicentre double-blind randomized controlled trial of ertanecept with or without methotrexate in patients with Psoriasic Arthritis
PI: Professor Petros Sfikakis
Double blind randomized controlled trial end of treatment of ertanecept compared to methotrexate in patients with Rheumatoid Arthritis in terms of disease progression
PI: Professor Petros Sfikakis
Multicentre double-blind randomized controlled trial Phase 3 comparing effectiveness and efficacy of apremilase (CC-10004) compared to placebo in patients with Behcet’s disease
PI: Professor Petros Sfikakis
Evaluation of Stelara® (Ustekinumab) and anti-TNF treatment in patients with Psoriasic Arthritis. Observational cohort study
PI: Professor Petros Sfikakis
Phase 3 randomised double blind controlled trial comparing effectiveness, safety and tolerance of secukinumab (150 mg and 300 mg) to placebo in patients with active Psoriasic Arthritis for up to 2 years (FUTURE 5)
PI: Professor Petros Sfikakis
Randomised double blind multicentre controlled trial comparing efficacy of secukinumab to adalimumab for 52 weeks in patients with active Psoriasic Arthritis
PI: Professor Petros Sfikakis
Randomised double blind controlled trial comparing efficacy of secukinumab for the treatment of Achilles tenontiitis up to 1 year in patients with active Psoriasic Arthritis (PsA) and axonal spondyloarthritis (axSpA) (ACHILLES)
PI: Professor Petros Sfikakis
Long Term experience with abatacept Sub Cutaneous in routine clinic alpractice-(ASCORE)
PI: Professor Petros Sfikakis
Long term prospective observational study of secukinumab in adult patients with moderaite to severe Psoriasis, Psoriasic Arthritis or Spondylatis (SERENA)
PI: Ass. Professor Maria Tektonidou
Golimumab effect on clinical outcome of patients with Rheumatoid Arhtitis in Greece (Go-Q Study)
PI: Ass. Professor Maria Tektonidou
Golimumab effect in productivity and quality of life in patients with Spondylitis, axonal Spondyloartropathy, axonal Spondyloarthropathy without radiology and Psoriasic Arthritis (GO –UP)
PI: Ass. Professor Maria Tektonidou
Registry of Bosentan administration in patients with Systemic Scleroderma
Support: ELPEN